Press Release: Sanofi supporting vulnerable communities as part of
commitment to social impact and fight against climate change
Sanofi supporting vulnerable communities as part
of commitment to social impact and fight against climate change
Paris, September
19, 2023 – As global leaders
gather at the United Nations’ 78th General Assembly, Sanofi is
delivering vital support to communities beset by climate turbulence
and by unmet medical needs. These critical initiatives come as the
global healthcare company
confirms its commitment
to positively impact society by
tackling climate
change and its
consequences for human
health.
Ramping up adaptation efforts and initiatives to
address the impact of
climate change on the health of vulnerable
communities becomes increasingly
critical. Through Foundation S, Sanofi’s
philanthropic organization, the company is strengthening locally
led adaptation and health resilience programs for vulnerable
communities impacted by climate change. Foundation
S is today
pledging nearly EUR 40 million
through 2030 to support
these efforts.
Paul HudsonChief Executive
Officer, Sanofi“Since 2015 and COP21, where Sanofi was the first
and only pharmaceutical company discussing climate change and its
impact on human health, we have been making strides to reduce the
emissions of our supply chain and minimize the impact our products
have on the environment. As we build our road to carbon neutrality
by 2030, we also want to help address the broader impacts of
climate change on the health of populations by teaming up with all
stakeholders. By working with governments, health professionals,
patient groups, regulators we can accelerate the decarbonization of
healthcare systems, and by expanding our investments in the
development of adaptation solutions for climate vulnerable
communities. All our company commitments are rooted in concrete,
transparent actions and driven by the greater sense of
responsibility of playing our part in the global adaptation and
fight against climate change.”
Sanofi starts in its own ‘climate’
backyard
In line with its objective to get to carbon
neutrality by 2030, Sanofi is advancing a holistic,
company-wide ambition to
minimize the environmental impact of its
products and activities, across its value
chain, while strengthening resilience to environmental changes. To
support its strategy, Sanofi plans to
invest over EUR 450 million through
2030. These investments notably support
company programs on energy efficiency and decarbonization of energy
supplies, as well as resource circularity - reduce, reuse, recycle
and recover - and reduction of natural resource extraction for
water for instance.
Committed to the United Nation’s Race to Zero
initiative, the company is building the road to carbon neutrality
across all scopes of emissions by 2030, and net zero greenhouse gas
emissions by 2045, five years earlier than previous targets. By the
end of 2022, greenhouse gas emission had decreased 29% compared to
2019 in scopes 1 & 2 and by 7% in scope 3. In addition, the
company has taken an end-to-end approach to reduce the
environmental footprint of its products. For example, by 2027, the
use of plastic in blister packs for all vaccines will be
eliminated. Today, the company is at 33%. Also, 62% of electricity
supplied on corporate sites is renewable with a target of 100% by
2030. Sanofi’s latest state-of-the-art facilities, such as its
Evolutive Facilities of Neuville-sur-Saône in southern France and
in Singapore, both set to open in 2025, are carbon-neutral by
design, with zero landfilling and 100% of the waste recycled or
recovered.
Several pilot programs have also been conducted
to assess how Sanofi’s most innovative products can contribute to
reducing emissions along the care pathway. The programs, evaluating
medicines and vaccines for RSV, atopic dermatitis, and flu, show
that prevention, reduced hospitalizations, decreased outpatient
visits and fewer patient consultations have a positive impact on
CO2 emissions while improving patients’ health outcome.
Additionally, a pilot program on the benefits of utilizing
telemedicine for patients with atopic dermatitis showed reduced CO2
emission attributed to less frequent healthcare professionals’
visits while also improving patient comfort and outcomes. Sanofi
will continue to implement pilot programs to advance data and
understanding of the co-benefits of best-in-class therapies that
can improve health outcomes while reducing greenhouse gas
emissions.
Josep
CatllàHead of Corporate Affairs,
Sanofi“Sustainability is at the core of Sanofi’s long-term
strategy, and it is ingrained in our mindset and behaviors in
everything we do. Whether it’s about accelerating our environmental
commitments, improving access to healthcare for vulnerable
populations, or building a diverse, equitable and inclusive
workplace, we’re driven by the ambition to make a sustainable
positive impact for our people, our communities and society
overall. This is why we are taking the initiative to help
communities around the world to work towards the decarbonization of
healthcare systems, which today account for more carbon emissions
than air transport. By working with local governments and
healthcare actors to significantly reduce those emissions, and by
continuing our essential work in delivering first- and
best-in-class medicines and vaccines, we double our impact to make
our planet healthier.”
Joining forces to go one step
further
Beyond reducing emissions from operations and
its supply chain, Sanofi is focused on decarbonization of
healthcare systems and sustainable delivery of care. The healthcare
sector is responsible for 5% of total net emissions and the patient
care pathway accounts for over 40% of that total. Sanofi is a
leading member of the SMI Health Systems Taskforce, a public and
private partnership of healthcare leaders launched at COP26, with
an ambition to accelerate delivery of net zero, patient centric
health systems. Sanofi is currently leading several key
initiatives, notably the Patient Care Pathway group, focused on
establishing an international measurement framework to calculate
the carbon emissions of the patient care journey, the development
of an industry product Life-Cycle-Assessment framework and a tool
to measure the impact of pharmaceutical products on climate.
Sanofi @
United Nations General
Assembly
Sanofi will host side events at the 78th UN
General Assembly, on September 20. Sanofi’s Foundation
S, in partnership with Foreign Policy and Africa Europe
Foundation will host Time to Adapt: Accelerating Climate
Adaptation for Health, a high-level strategic dialogue to
spotlight the health impacts of climate change and to mobilize on
the financial need required to support community-led climate
adaptation efforts in low- and –middle-income countries. Despite
contributing the least to climate change, low- and middle-income
countries (LMICs) are most affected by its consequences, including
increased morbidity and mortality, loss of livelihoods, and forced
migration.
As part of its work, Foundation S has launched
several first-in-class grant programs to enhance the capacity of
communities to prepare for and respond to climate-related impacts
on health. To further raise awareness about the need for and
importance of strengthening and funding climate adaptation and
health resilience initiatives at the local level in climate
vulnerable countries, the Collective MindS think thank will publish
on September 20, 2023 an Action Report that highlights adaptation
solutions that can be replicated and brought to scale, and will
call for urgent multi-lateral action to address the health impacts
of climate change at the community level.
Sanofi’s Global Health Unit
side event ‘Unlocking Universal Health Coverage 2030: The
Power of Health Financing’, co-organized
with the Health Finance Institute (HFI), will focus on mobilizing
stakeholders on the need for financial sustainability, sufficiency,
and tools for better access to healthcare, while sharing Sanofi’s
Global Health Unit Model. HFI will present the conclusions of
research supported by Sanofi on healthcare financing and highlight
that focus on higher efficiency and collaboration among different
actors is key.
About SanofiWe are an innovative global
healthcare company, driven by one purpose: we chase the miracles of
science to improve people’s lives. Our team, across some 100
countries, is dedicated to transforming the practice of medicine by
working to turn the impossible into the possible. We provide
potentially life-changing treatment options and life-saving vaccine
protection to millions of people globally, while putting
sustainability and social responsibility at the center of our
ambitions. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Media RelationsSandrine
Guendoul | + 33 6 25 09 14 25
| sandrine.guendoul@sanofi.comEvan Berland |
+1 215 432 0234 | evan.berland@sanofi.comVictor
Rouault | + 33 6 70 93 71 40
| victor.rouault@sanofi.com
Investor RelationsEva
Schaefer-Jansen | + 33 7 86 80 56 39
| eva.schaefer-jansen@sanofi.comArnaud
Delépine | + 33 6 73 69 36 93 |
arnaud.delepine@sanofi.comCorentine
Driancourt | + 33 6 40 56 92 21 |
corentine.driancourt@sanofi.comFelix
Lauscher | + 1 908 612 7239 |
felix.lauscher@sanofi.comTarik Elgoutni| + 1 617
710 3587 | tarik.elgoutni@sanofi.comNathalie
Pham | + 33 7 85 93 30 17 |
nathalie.pham@sanofi.com
Sanofi Forward Looking
StatementThis press release contains forward-looking
statements as defined in the Private Securities Litigation Reform
Act of 1995, as amended. Forward-looking statements are statements
that are not historical facts. These statements include projections
and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with
respect to future financial results, events, operations, services,
product development and potential, and statements regarding future
performance. Forward-looking statements are generally identified by
the words “expects”, “anticipates”, “believes”, “intends”,
“estimates”, “plans” and similar expressions. Although Sanofi’s
management believes that the expectations reflected in such
forward- looking statements are reasonable, investors are cautioned
that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of Sanofi, that could
cause actual results and developments to differ materially from
those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include
among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or
the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the fact that product candidates if
approved may not be commercially successful, the future approval
and commercial success of therapeutic alternatives, Sanofi’s
ability to benefit from external growth opportunities, to complete
related transactions and/or obtain regulatory clearances, risks
associated with intellectual property and any related pending or
future litigation and the ultimate outcome of such litigation,
trends in exchange rates and prevailing interest rates, volatile
economic and market conditions, cost containment initiatives and
subsequent changes thereto, and the impact that pandemics or other
global crises may have on us, our customers, suppliers, vendors,
and other business partners, and the financial condition of any one
of them, as well as on our employees and on the global economy as a
whole. The risks and uncertainties also include the uncertainties
discussed or identified in the public filings with the SEC and the
AMF made by Sanofi, including those listed under “Risk Factors” and
“Cautionary Statement Regarding Forward-Looking Statements” in
Sanofi’s annual report on Form 20-F for the year ended December 31,
2022. Other than as required by applicable law, Sanofi does not
undertake any obligation to update or revise any forward-looking
information or statements.
Sanofi (BIT:1SAN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Sanofi (BIT:1SAN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024